A STUDY EXAMINING TORCETRAPIB/ATORVASTATIN AND ATORVASTATIN EFFECTS ON CLINICAL CV EVENTS IN PATIENTS WITH HEART DISEASE:

***Note December 2006: The development of torcetrapib has been terminated because of increased mortality and cardiovascular events compared with Lipitor alone. Atrovastatin (Lipitor) continues to be a valuable cardiovascular drug with an excellent safety profile.***

***Note October 2006: This Pfizer-sponsored trial has now completed patient enrollment. It is included here merely to illustrate the use of the Internet for patient enrollment in clinical trials.***

A brief description of this clinical trial is given below, followed by questions to check some of the eligibility criteria (the requirements that a patient must meet before entering the trial). The questions also list the locations of the many study sites (hospitals, clinics or doctors taking part in the trial) and ask for your preferred study site(s) if you are recruited for the trial. You will also be asked if you are still interested in participating in the study after reviewing the material; if so, you will be asked if you want the study site to contact you directly or prefer to contact the study site yourself. On completion of the questionnaire, you will be informed if this preliminary evaluation suggests that you may be eligible for the trial. If so, you would be evaluated further by the study site before actually entering the trial.

PARTIAL SUMMARY OF TRIAL:
Purpose: To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents.
Drugs: torcetrapib/atorvastatin combination, atorvastatin alone
Trial Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: " Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents"
Primary Outcomes: The time to first occurrence of a major cardiovascular disease event.
Secondary Outcomes: Various composites of major cardiovascular disease events and other lipid parameters.
Expected Total Enrollment: 13,000
Study start: July 2004

This questionnaire is intended for use in and by adults, and should take about 10 minutes to complete. You should not use this questionnaire for self-diagnosis or as a substitute for seeing a healthcare professional. The questionnaire is best viewed with your screen resolution set at 1024 x 768 and not too many toolbars taking up space at the top of the screen. Type in your answers. Click "Continue" at the foot of each page to go to the next page. On most browsers, clicking "Tab" when inside a field takes you to the next field. To go back to a previous page, click the "Back" button on your browser (or right click mouse and select "Back"). You can scroll with the up/down and left/right buttons if you can’t see the full page on your screen. Ignore questions if you don't presently have the information, if they don't apply to you, or if you just prefer to leave them blank.

YOUR PRIVACY: TMT makes extensive efforts to protect your personally identifying information but cannot absolutely guarantee such protection. Accordingly, you should carefully weigh the advantages and disadvantages of providing personal information. We will not provide your information to third parties without your prior permission. We use Secure Sockets Layer technology for Internet data transfer. Some, but not all, TMT's questionnaires are protected under a Confidentiality Certificate (CC) from the US Government's National Institutes of Health (see our privacy policy at: http://masterdocs.com/privacy_policy.htm). Since there is a very small chance that someone could improperly get the Internet link to your report, we suggest you provide a password for additional protection. If you prefer to answer the questionnaire anonymously, don't fill in the fields that identify you, such as your name (you can then insert the missing information yourself after we provide your report). You can also use an anonymous email address if you want (Microsoft, Yahoo and others offer free email addresses).